Andrew P. Mazar's most recent trade in Actuate Therapeutics Inc. was a trade of 110,346 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Actuate Therapeutics Inc. | Andrew P. Mazar | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 110,346 | 110,346 | - | - | Employee Stock Option (right to buy) | |
| Actuate Therapeutics Inc. | Andrew P. Mazar | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 51,046 | 51,046 | - | - | Employee Stock Option (right to buy) | |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 1,606 | 88,792 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 1,606 | 22,595 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.55 per share. | 31 Mar 2022 | 471 | 22,124 (0%) | 0% | 2.5 | 1,201 | Common Stock |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 1,937 | 3,874 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 1,937 | 21,660 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.21 per share. | 01 Jan 2022 | 671 | 20,989 (0%) | 0% | 3.2 | 2,154 | Common Stock |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2021 | 3,212 | 18,480 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2021 | 3,212 | 22,485 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.89 per share. | 30 Jun 2021 | 942 | 17,538 (0%) | 0% | 5.9 | 5,548 | Common Stock |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 36,077 | 36,077 | - | - | Stock Options | |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 25,697 | 31,508 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2021 | 1,937 | 5,811 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2021 | 1,937 | 15,939 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Andrew P. Mazar | Director, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 01 Jan 2021 | 671 | 15,268 (0%) | 0% | 6.1 | 4,107 | Common Stock |